Ken Griffin Aeglea Bio Therapeutics, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.35 - $1.54 $15,856 - $69,766	-45,303 Reduced 74.54%	15,472 $6,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.81 $63,239 - $134,800	-166,420 Reduced 73.25%	60,775 $32,000
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $76,890 - $409,057	153,781 Added 209.47%	227,195 $115,000
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $74,231 - $189,349	39,696 Added 117.73%	73,414 $169,000
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $96,918 - $135,712	-13,806 Reduced 29.05%	33,718 $265,000
Q3 2020 Nov 16, 2020	BUY	$6.51 - $9.33 $126,170 - $180,824	19,381 Added 68.87%	47,524 $337,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $17,856 - $49,161	4,453 Added 18.8%	28,143 $261,000
Q1 2020 May 15, 2020	BUY	$3.51 - $8.48 $32,239 - $77,888	9,185 Added 63.32%	23,690 $110,000
Q4 2019 Feb 14, 2020	SELL	$7.23 - $8.55 $110,069 - $130,165	-15,224 Reduced 51.21%	14,505 $111,000
Q2 2019 Aug 14, 2019	SELL	$6.1 - $8.78 $545,718 - $785,476	-89,462 Reduced 75.06%	29,729 $203,000
Q1 2019 May 15, 2019	BUY	$7.6 - $9.4 $905,851 - $1.12 Million	119,191 New	119,191 $0

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.